



**General Medicine  
NAUSEA AND VOMITING  
Practice Guideline**

**Patient Care Goals**  
Decrease discomfort secondary to nausea and vomiting

**Patient Presentation:**  
Inclusion Criteria  
Patient experiencing nausea and/or vomiting

Exclusion Criteria  
History of congenital/acquired prolonged QTc syndrome

**Patient Management:**  
Apply Universal Care Guideline to assess for underlying conditions causing nausea and/or vomiting  
Nausea and/or vomiting are symptoms and not a diagnosis

**Medications**  
Ondansetron  
ODT: 15-30kg: 4 mg  
>30kg: 8 mg  
IV/IO: 0.1 mg/kg MAX 4 mg

Diphenhydramine  
IV/IO/IM: 1 mg/kg MAX 25 mg  
(IV/IO Slow push over 2 mins)

**Patient Safety Considerations:**

- At larger doses than our Practice Guidelines allow, ondansetron may pose risk in patients with prolonged QTc >470 ms. An ECG solely to determine QTc is unnecessary prior to administering ondansetron within Practice Guideline ranges but may be used as another data point or if the dosing is exceeded in conjunction with OLMC.
- There is inconclusive/inadequate data on safety of ondansetron in first trimester pregnancy; dose range within our Practice Guideline range is reasonable.

**Quality Improvement:**  
Per Operational Policy 'Narrative and Events Documentation'

**Performance Measures**  
Response to medication administration

